6. パーキンソン病 Parkinson disease Clinical trials / Disease details

臨床試験数 : 2,307 / 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199

13 trials found

diseases per page:

Showing 1 to 10 of 13 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04226248 (ClinicalTrials.gov)	January 2, 2020	5/12/2019	CHIEF PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease)	CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease: A Phase 3 Randomised, Double-blind ...	Parkinson Disease	Drug: Rivastigmine Transdermal System;Other: Placebo Transdermal System	University of Bristol	Royal United Hospitals Bath NHS Foundation Trust	Recruiting	18 Years	N/A	All	600	Phase 3	United Kingdom
2	EUCTR2018-003219-23-GB (EUCTR)	28/06/2019	04/06/2019	CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson’s Disease)	CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson’s Disease): A phase 3 randomised do ...	This trial will investigate the effectiveness of Rivastigmineon prevention of falls in patients with ...	Trade Name: Rivastigmin Luye Transdermal Patches - 4.6mg/24h Product Name: Rivastigmin Luye Transderm ...	University of Bristol	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	600	Phase 3	United Kingdom
3	NCT03840837 (ClinicalTrials.gov)	May 2, 2019	11/2/2019	Cholinergic Neurotransmission in Mobility and Cognition in Parkinson Disease	Cholinergic Neurotransmission - A Common Underlying Mechanism of Cognitive and Gait Impairment in Pa ...	Parkinson Disease;Parkinson Disease Dementia	Drug: Rivastigmine transdermal patch	University of Maryland, Baltimore	National Institute on Aging (NIA)	Completed	18 Years	N/A	All	31	Phase 4	United States
4	NCT01856738 (ClinicalTrials.gov)	November 2013	14/5/2013	Cholinesterase Inhibitors to Slow Progression of Visual Hallucinations in Parkinson&Apos;s Disease	Cholinesterase Inhibitors to Slow Progression of Visual Hallucinations in Parkinson's Disease:a Mult ...	Parkinson's Disease	Drug: Rivastigmine;Drug: Placebo (for rivastigmine)	VU University Medical Center	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA);Atrium Medical Center;University M ...	Terminated	40 Years	N/A	All	91	Phase 4	Netherlands
5	EUCTR2013-001722-25-NL (EUCTR)	27/08/2013	12/08/2013	Rivastigmine as an early treatment for visual hallucinations in Parkinson’s disease (CHEVAL)	Cholinesterase inhibitors to slow progression of visual hallucinations in Parkinson’s disease: a mul ...	Parkinson's disease MedDRA version: 18.0;Level: PT;Classification code 10061536;Term: Parkinson's di ...	Trade Name: Rivastigmine CF	VU University Medical Center	NULL	Not Recruiting			Female: yes Male: yes	168	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (P ...	Netherlands
6	EUCTR2011-003053-25-GB (EUCTR)	18/06/2012	01/05/2012	The ReSPonD Study -Rivastigmineto Stabilise gait in Parkinson’s Disease. A study looking at whether ...	A randomised, double blind, placebo controlled trial to evaluate the effect of Rivastigmineon gait i ...	Parkinson's disease MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's di ...	Trade Name: Exelon ® Product Name: ENA713 Product Code: N/A INN or Proposed INN: Rivastigmine Trade Name: ...	Research and Enterprise Department	NULL	Not Recruiting			Female: yes Male: yes	130	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - ( ...	United Kingdom
7	NCT01519271 (ClinicalTrials.gov)	December 2011	10/1/2012	Mild Cognitive Impairment in Parkinson's Disease	A Phase IV Randomized, Double-Blind, Placebo-Controlled, Crossover Single Site Study Of Exelon® Patc ...	Parkinson's Disease;Mild Cognitive Impairment	Drug: Exelon Patch (rivastigmine transdermal system);Drug: Placebo Patches	University of Pennsylvania	NULL	Completed	40 Years	85 Years	All	28	Phase 4	United States
8	NCT00988117 (ClinicalTrials.gov)	April 2010	29/9/2009	The Effects of the Rivastigmine Patch on Parkinson's Disease With Memory and/or Thinking Problems	The Effects of the RivastigminePatch on Attention and Behavior in Parkinson's Disease With Dementia ...	Parkinsons Disease With Dementia;Parkinsons Disease With Mild to Moderate Memory and/or Thinking Pro ...	Drug: Rivastigmine Patch 9.5 cm2	University of California, San Francisco	Novartis	Completed	55 Years	N/A	All	15	Phase 4	United States
9	NCT00767091 (ClinicalTrials.gov)	March 2009	1/9/2008	Study of Rivastigmine to Treat Parkinsonian Apathy Without Dementia	A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicentric Trial	Parkinson's Disease;Apathy;no Dementia	Drug: rivastigmine;Drug: placebo	University Hospital, Lille	NULL	Completed	15 Years	80 Years	Both	40	Phase 3	France
10	EUCTR2007-000350-31-IT (EUCTR)	02/10/2008	11/02/2008	A 76-week prospective, open-label, multicenter study to evaluate the long-term effect of Exelon caps ...	A 76-week prospective, open-label, multicenter study to evaluate the long-term effect of Exelon caps ...	mild to moderately severe dementia associated with Parkinson?s disease (PDD) MedDRA version: 9.1;Lev ...	Product Name: Exelon path transdermal Product Code: ENA713B INN or Proposed INN: Rivastigmine Trade Name ...	NOVARTIS FARMA	NULL	Not Recruiting			Female: yes Male: yes	550		France;Spain;Italy

First Previous1 2Next Last